CHAPTER FOUR: MARKET SIZE AND GROWTH SLEEP MEDICATIONS MARKET PRESCRIPTION... 40

Similar documents
The U.S. Sleep Market: A Market, Competitive & Operating Analysis

CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES. SEDATIVE HYPNOTIC AGENTS Generic Brand HICL GCN Exception/Other ZOLPIDEM

ANESTHESIA AND RESPIRATORY DEVICES: GLOBAL MARKETS. HLC167A February Vijay Laxmi Project Analyst ISBN:

Insomnia Agents (Sherwood Employer Group)

See Important Reminder at the end of this policy for important regulatory and legal information.

U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),

ADULT ENTERAL NUTRITION PARENTERAL NUTRITION U.S. REGULATORY ENVIRONMENT THE INFANT FORMULA ACT OF The 1986 Amendments

The Medical Letter. on Drugs and Therapeutics. Usual Adult Hypnotic Dose 1,2 Some Adverse Effects Comments Cost 3

See Important Reminder at the end of this policy for important regulatory and legal information.

Insomnia treatment. Sleep hygiene education sleep hygiene teaches good sleeping habits. This includes:

Insomnia: Updates in Medical Management. Michael Newnam M.D.

Insomnia. Arturo Meade MD

CHAPTER ONE: EXECUTIVE SUMMARY

See Important Reminder at the end of this policy for important regulatory and legal information.

Sleep apnea devices Market Research Report- Global Forecast To 2022

Oventus: Innovators in Sleep Apnoea Treatment Investor lunch presentation Tattersall s Club, Brisbane

U.S. AND GLOBAL MARKETS FOR ETHICAL NUTRITION IN HEALTHCARE

Available Strengths Limits. 200 mg tablets PA. 50 mg, 150 mg, 200 mg, 250 mg tablets. 500 mg/ml solution PA

Operatory Units TABLE 20 SELECT MANUFACTURERS AND DISTRIBUTORS OF DENTAL FURNITURE TABLE 20 (CONTINUED) Cavity Preparation Systems

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:

Sleep 101. Kathleen Feeney RPSGT, RST, CSE Business Development Specialist

Comparison of Insomnia Treatments

Facts about Sleep. Circadian rhythms are important in determining human sleep patterns/ sleep-waking cycle

14. Percent Mellinger GD et al. Arch Gen Psychiatry. 1985;42: ICSD III

Pharmacological Help for a Good Night s s Sleep. Thomas Owens, MD

Insomnia treatment in primary care

Sleep Disorders The Effect on our Lives Every Day

Ambien vs Rozerem There are people out there who have trouble falling asleep at night. Â Often, this would be considered as a disease that

Information for Vermont Prescribers of Prescription Drugs. Lunesta (eszopiclone tablets)

CHAPTER ONE: EXECUTIVE SUMMARY. The Global Vaccine Industry CHAPTER TWO: INTRODUCTION TO VACCINES

Get on the Road to Better Health Recognizing the Dangers of Sleep Apnea

Sleep Disorders and Insomnia

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS

Sedative Hypnotics. Description

CHAPTER ONE: EXECUTIVE SUMMARY

14. Percent

THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR

Pharmacy Medical Necessity Guidelines: Insomnia Treatments

Pharmacy Benefit Determination Policy

Sedative Hypnotics. Description

PHM029D - Antifungal Drugs: Technologies and Global Markets TABLE OF CONTENTS

Financial Presentation

Global Continuous Positive Airway Pressure(CPAP) Devices Market Research Report - Forecast to 2027

Managing Sleep Disorders in Primary Care. Objectives. Disclosures. Nancy Nadolski, FNP, MSN, M.Ed Insomnia Medicine of Idaho Boise Counseling Center

INTRAVENOUS (IV) THERAPY AND VEIN ACCESS: GLOBAL MARKETS

Itamar Medical. December Investors Presentation.

Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF

Article printed from

DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

Disclosures. Speaker: Teva, UCB, Purdue Advisory Board: Welltrinsic Sleep Network Consultant: Vapotherm, Inc. National Interpretor: Novasom

Modern Management of Sleep Disorders. If Only I Could Sleep Like I Did Before

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )

TABLE 4 U.S. TEETH CLEANING VISITS BY SELECTED CHARACTERISTICS (%) TABLE 4 (CONTINUED) FIGURE 2 U.S. POPULATION WITH TEETH CLEANING

(Incidence, Treatments, Key Companies, Pipeline and Trends)

Organ Transplantation Market Research Report- Global Forecast Till 2023

Ramelteon to ambien The Borg System is 100 % Retrievable & Reusable Ramelteon to ambien

Question #1. Disclosures. CAPA 2015 Annual Conference. All of the following occur as we get older EXCEPT: Evaluating Patients with Insomnia

Checklist for Completion of Training Requirements in Sleep Medicine Pathway 2

Global Magnetic Resonance Imaging (MRI) Systems Market Research Report 2016

Sleep Medicine. Maintenance of Certification Examination Blueprint. Purpose of the exam

HEALTHY LIFESTYLE, HEALTHY SLEEP. There are many different sleep disorders, and almost all of them can be improved with lifestyle changes.

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B

How to Manage Insomnia with and without medications

Sleep Science: better sleep for you and your patients CHUNBAI ZHANG, MD MPH UW MEDICINE VALLEY MEDICAL CENTER

US Tardive Dyskinesia Market: Size, Trends & Forecasts ( ) December 2016

Sleep and Ageing. Siobhan Banks PhD. Body and Brain at Work, Centre for Sleep Research University of South Australia

TABLE OF CONTENTS. HLC102A - Continuous Glucose Monitoring (CGM): Technologies and Global Markets

Vaccine Technologies and Global Markets

CHAPTER THREE: INDUSTRY OVERVIEW... 6 STRUCTURE AND HISTORY OF THE DENTAL INDUSTRY... 6 STRUCTURE AND HISTORY (CONTINUED)... 8

An Introduction to Sleep Medicine & Sleep-Related Breathing Disorders

ASX Investor Presentation

Can you take sleeping pills with ativan

EU5 Bariatric Surgery Procedures Outlook to 2020

Sleep and Students. John Villa, DO Medical Director

Home Bipap Respironics Guide

Modern Management of Sleep Disorders. Case. Introduction. Topics Covered. Douglas C. Bauer, MD University of California, San Francisco

Prescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service

Index. sleep.theclinics.com. Note: Page numbers of article titles are in boldface type.

Modern Management of Sleep Disorders

CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS

Global Standard Radiography Film X-Ray Film Printer Market Research Report 2016

The Importance of Sleep to a Healthy Workplace

Global Pulse Oximetry Market: Trends and Opportunities ( )

GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst

Managing Insomnia Disorder A Review of the Research for Adults

States of Consciousness Sleep, Dreams, Hypnosis

Global Oil Softgel Capsules Market Research Report 2016

The Future of Sleep Medicine

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast

Contraceptives: Technologies and Global Markets

BRIC DIABETES DRUGS MARKET

CPAP. The CPAP will be covered

Polysomnography Course Session: Sept 2017

Global Hearing Aids Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast to 2022

WHY CAN T I SLEEP? Deepti Chandran, MD

Respironics Home Bipap Manual

Transcription:

CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 BCC ONLINE SERVICES... 3 DISCLAIMER... 3 CHAPTER TWO: EXECUTIVE SUMMARY... 4 EXECUTIVE SUMMARY... 4 EXECUTIVE SUMMARY (CONTINUED)... 5 EXECUTIVE SUMMARY (CONTINUED)... 6 SUMMARY TABLE A TOTAL WORLDWIDE MARKET FOR SLEEP AIDS BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS)... 7 SUMMARY TABLE B WORLWIDE MARKET FOR SLEEP AIDS: TECHNOLOGIES AND MARKETS BY REGION, 2008-2014 (%)... 8 SUMMARY FIGURE PERCENT OF TOTAL WORLWIDE MARKET FOR SLEEP AIDS: TECHNOLOGIES AND MARKETS BY REGION, 2014 (%)... 8 CHAPTER THREE: INDUSTRY OVERVIEW... 9 PHYSIOLOGY OF SLEEP... 9 STAGES OF SLEEP... 9 NREM Sleep... 10 Stage 1... 10 Stage 2... 10 Stage 3... 10 Stage 4... 10 REM Sleep... 11 SLEEP CYCLE... 12 BIOLOGICAL CLOCK... 12 FACTORS AFFECTING SLEEP... 13 COMFORT LEVEL... 13 ANXIETY AND STRESS... 13 CULTURAL NORMS... 13 DRUGS/MEDICATIONS... 14 ENVIRONMENT... 14 HORMONES... 14 LIFESPAN CONSIDERATIONS... 14 Lifespan Considerations (Continued)... 15 LIFESTYLE... 16 NUTRITION/DIET... 16

ALTERATION IN SLEEP PATTERNS... 16 INSOMNIA... 17 Psychological Insomnia... 17 Idiopathic Insomnia... 17 Sleep-State Misinterpretation... 18 NARCOLEPSY/HYPERSOMNIA... 18 SLEEP APNEA AND SNORING... 18 PARASOMNIA... 19 SLEEP DEPRIVATION... 20 DEMOGRAPHICS... 20 TABLE 1 WORLD POPULATION BY SELECTED GEOGRAPHICAL REGION, 2008 2050 (MILLIONS)... 21 TABLE 2 ESTIMATED WORLD POPULATION BY AGE AND GEOGRAPHICAL REGION, 2008 (MILLIONS)... 21 TABLE 2 (CONTINUED)... 22 TABLE 3 PERCENTAGE OF WORLWIDE POPULATION OVER 65 BY YEAR AND REGION, 2008 2050 (%)... 22 FIGURE 1 PERCENTAGE OF WORLDWIDE POPULATION OVER 65 BY YEAR AND REGION, 2008 2050 (%)... 23 PREVALENCE OF SLEEP APNEA... 24 TABLE 4 PREVALENCE OF SLEEP APNEA WORLDWIDE BY REGION AND COUNTRY, 2006... 24 TABLE 4 (CONTINUED)... 25 TABLE4 (CONTINUED)... 26 TABLE 4 (CONTINUED)... 27 OTHER SLEEP DISORDER STATISTICS... 27 TABLE 5 U.S. OTHER SLEEP DISORDER STATISTICS 2008... 27 NARCOLEPSY... 28 RESTLESS LEG SYNDROME... 29 SUBSTANCE ABUSE AND SLEEP DISORDERS... 29 ALTERNATIVE SNORING AIDS... 30 ALTERNATIVE SNORING AIDS (CONTINUED)... 31 REIMBURSEMENT... 32 SLEEP AND THE ELDERLY... 33 DROWSY DRIVING... 33 HOME TESTING... 34 HOME TESTING (CONTINUED)... 35 OTHER SLEEP PRODUCTS... 36 OBESITY AND SLEEP PROBLEMS... 37 INNOVATIVE COST-SAVING PROGRAMS... 38 INNOVATIVE COST-SAVING PROGRAMS (CONTINUED)... 39 CHAPTER FOUR: MARKET SIZE AND GROWTH... 40 SLEEP MEDICATIONS MARKET... 40 PRESCRIPTION... 40

Benzodiazepines... 40 ProSom... 41 Dalmane... 41 Doral... 42 Restoril... 42 Halcion... 42 Nonbenzodiazepines... 43 Lunesta... 43 Ambien... 44 Sonata... 44 Melatonin Receptor Agonists... 45 Rozerem... 45 Narcolepsy Treatment... 46 Provigil... 46 Restless Leg Syndrome... 46 ReQuip... 46 Mirapex... 46 Neupro... 47 TABLE 6 GLOBAL SELECTED MARKETED PRESCRIPTION SLEEP AIDS, 2008 ($ MILLIONS)... 47 TABLE 6 (CONTINUED)... 48 OTC... 48 Medications... 48 Medications (Continued)... 49 TABLE 7 GLOBAL SELECTED MARKETED OTC SLEEP AIDS, 2008 ($ MILLIONS)... 50 Natural Remedies... 50 Herbs... 50 Melatonin... 51 Tryptophan, L-tryptophan... 51 New Over-the-Counter Sleep Aids... 51 New Over-the- (Continued)... 52 SLEEP MEDICATION MARKET SIZE AND FORECAST... 53 TABLE 8 GLOBAL MARKET FOR SLEEP AID MEDICATIONS AT MANUFACTURERS SALES LEVELS, THROUGH 2014 ($ MILLIONS)... 54 FIGURE 2 GLOBAL MARKET FOR SLEEP AID MEDICATIONS AT MANUFACTURERS SALES LEVELS, THROUGH 2014 ($ MILLIONS)... 54 TABLE 9 GLOBAL MARKET FOR PRESCRIPTION SLEEP AID MEDICATIONS BY TYPE AT MANUFACTURERS SALES LEVELS, THROUGH 2014 ($ MILLIONS)... 55

FIGURE 3 GLOBAL MARKET FOR PRESCRIPTION SLEEP AID MEDICATIONS BY TYPE AT MANUFACTURERS SALES LEVELS, THROUGH 2014 ($ MILLIONS)... 56 TABLE 10 GLOBAL MARKET FOR OTC SLEEP AID MEDICATIONS BY DRUG CLASS AT MANUFACTURERS SALES LEVELS, THROUGH 2014 ($ MILLIONS)... 57 FIGURE 4 GLOBAL MARKET FOR OTC SLEEP AID MEDICATIONS BY DRUG CLASS AT MANUFACTURERS SALES LEVELS, 2008-2014 ($ MILLIONS)... 57 United States... 58 European Union... 58 Japan... 58 Rest of World... 59 TABLE 11 GLOBAL MARKET FOR SLEEP AID MEDICATIONS BY REGION, THROUGH 2014 ($ MILLIONS)... 59 FIGURE 5 GLOBAL MARKET FOR SLEEP AID MEDICATIONS BY REGION, 2008-2014 ($ MILLIONS)... 60 TABLE 12 GLOBAL PERCENTAGE OF MARKET FOR SLEEP AID MEDICATIONS BY REGION, 2008-2014 (%)... 60 FIGURE 6 GLOBAL PERCENTAGE OF MARKET FOR SLEEP AID MEDICATIONS BY REGION, 2008-2014 (%)... 61 COMPETITIVE ANALYSIS OF THE PRESCRIPTION AND OTC SLEEP AID MEDICATIONS MARKET... 61 TABLE 13 GLOBAL COMPETITIVE ANALYSIS OF PRESCRIPTION AND OTC SLEEP AIDS BY DRUG MANUFACTURER REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%)... 62 FIGURE 7 GLOBAL COMPETITIVE ANALYSIS OF PRESCRIPTION AND OTC SLEEP AIDS BY DRUG MANUFACTURER REVENUES, 2009 ($ MILLIONS)... 63 SLEEP APNEA DEVICES MARKET... 63 SLEEP APNEA... 63 Obstructive Sleep Apnea... 64 Obstructive Sleep Apnea (Continued)... 65 Obstructive Sleep Apnea (Continued)... 66 Obstructive Sleep Apnea (Continued)... 67 Obstructive Sleep Apnea (Continued)... 68 Central Apnea... 69 Central Apnea (Continued)... 70 Mixed Apnea... 71 SLEEP APNEA THERAPEUTIC EQUIPMENT... 71 Flow Generators... 71 CPAP Devices... 72 Bi-Level PAP Devices... 72 APAP Devices... 72

Facial Interfaces... 72 SLEEP APNEA DEVICE MARKET SIZE AND FORECAST... 73 TABLE 14 GLOBAL MARKET FOR SLEEP APNEA DEVICES, THROUGH 2014 ($ MILLIONS)... 73 United States... 74 European Union... 74 Japan... 74 Rest of World... 74 TABLE 15 GLOBAL MARKET FOR SLEEP APNEA DEVICES BY REGION, THROUGH 2014 ($ MILLIONS)... 75 FIGURE 8 GLOBAL MARKET FOR SLEEP APNEA DEVICES BY REGION, 2008-2014 ($ MILLIONS)... 75 TABLE 16 GLOBAL MARKET FOR SLEEP APNEA DEVICES BY REGION, 2008-2014 (%)... 76 COMPETITIVE ANALYSIS OF THE SLEEP APNEA DEVICES MARKET... 76 TABLE 17 COMPETITIVE ANALYSIS OF SLEEP APNEA DEVICE MANUFACTURERS WITH GLOBAL MARKET SHARES AND REVENUES, 2009 ($ MILLIONS/%)... 77 FIGURE 9 COMPETITIVE ANALYSIS OF SLEEP APNEA DEVICE MANUFACTURERS WITH GLOBAL MARKET SHARES, 2009 (%)... 77 SLEEP LABORATORIES MARKET... 78 BACKGROUND OF SLEEP LABORATORIES... 78 SLEEP LAB PROTOCOLS... 78 Polysomnogram... 79 Split Night Study... 80 Multiple Sleep Latency Test... 80 CPAP Titration Study... 81 SLEEP LABORATORIES MARKET SIZE AND FORECAST... 81 TABLE 18 GLOBAL MARKET FOR SLEEP LABORATORIES BY REGION, THROUGH 2014 ($ MILLIONS)... 82 FIGURE 10 GLOBAL MARKET FOR SLEEP LABORATORIES BY REGION, 2008-2014 ($ MILLIONS)... 82 TABLE 19 GLOBAL MARKET FOR SLEEP LABORATORIES BY REGION, THROUGH 2014 (%)... 83 FIGURE 11 GLOBAL MARKET FOR SLEEP LABORATORIES BY REGION, 2014 (%)... 83 MATTRESS AND PILLOW MARKET... 84 MATTRESSES... 84 Innerspring... 84 Foam... 84 Air Beds... 84 Air Beds (Continued)... 85 PILLOWS... 86

Bed Pillows... 87 Orthopedic Pillows... 88 Decorative... 88 Decorative (Continued)... 89 MATTRESS AND PILLOW MARKET SIZE AND FORECAST... 90 TABLE 20 GLOBAL MARKET FOR MATTRESSES AND PILLOWS, THROUGH 2014 ($ MILLIONS)... 90 FIGURE 12 GLOBAL MARKET FOR MATTRESSES AND PILLOWS, 2008-2014 ($ MILLIONS)... 91 TABLE 21 GLOBAL MARKET FOR MATTRESSES AND PILLOWS BY REGION, THROUGH 2014 ($ MILLIONS)... 92 FIGURE 13 GLOBAL MARKET FOR MATTRESSES AND PILLOWS BY REGION, 2008-2014 ($ MILLIONS)... 92 TABLE 22 GLOBAL MARKET FOR MATTRESSES AND PILLOWS BY REGION, 2008-2014 (%)... 93 FIGURE 14 GLOBAL MARKET FOR MATTRESSES AND PILLOWS BY REGION, 2014 (%)... 93 COMPETITIVE ANALYSIS OF THE MATTRESS AND PILLOW MARKET... 94 Competitive Analysis of the Mattress (Continued)... 94 TABLE 23 GLOBAL COMPETITIVE ANALYSIS OF MATTRESS AND PILLOW MANUFACTURERS WITH MARKET SHARES AND REVENUES, 2009 ($ MILLIONS/%)... 95 FIGURE 15 GLOBAL COMPETITIVE ANALYSIS OF MATTRESS AND PILLOW MANUFACTURERS REVENUES, 2009 ($ MILLIONS)... 95 CHAPTER FIVE RESEARCH AND DEVELOPMENT... 96 RECENT APPROVALS... 96 EDLUAR... 96 ZOLPIMIST... 96 AWAITING APPROVAL... 97 CILTYRI... 97 INDIPLON... 97 INTERMEZZO... 97 SILENOR... 97 SOLZIRA... 98 PHASE III... 98 ALMOREXANT... 98 NUVIGIL... 99 VEC-162 (TASIMELTEON)... 99 TABLE 24 DRUGS IN DEVELOPMENT WORLDWIDE FOR SLEEP DISORDERS, 2009... 100 TABLE 24 (CONTINUED)... 101 NEW DEVELOPMENTS... 101 MARKET SUMMARY... 102

TOTAL MARKET... 102 TABLE 25 GLOBAL MARKET FOR SLEEP AIDS: TECHNOLOGIES AND MARKETS, THROUGH 2014 ($ MILLIONS)... 102 TOTAL MARKET BY PRODUCT TYPE... 102 TABLE 26 GLOBAL MARKET FOR SLEEP AIDS BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS)... 103 FIGURE 16 GLOBAL MARKET FOR SLEEP AIDS BY PRODUCT TYPE, 2008-2014 ($ MILLIONS)... 104 FIGURE 17 GLOBAL MARKET FOR SLEEP AIDS BY PRODUCT TYPE, 2009 (%)... 104 FIGURE 17 (CONTINUED)... 105 TOTAL MARKET BY GEOGRAPHIC REGION... 105 TABLE 27 GLOBAL MARKET FOR SLEEP AIDS: TECHNOLOGIES AND MARKETS BY REGION, THROUGH 2014 ($ MILLIONS)... 106 FIGURE 18 GLOBAL MARKET FOR SLEEP AIDS: TECHNOLOGIES AND MARKETS BY REGION, THROUGH 2014 ($ MILLIONS)... 106 TABLE 28 GLOBAL MARKET FOR SLEEP AIDS: TECHNOLOGIES AND MARKETS BY REGION, 2008-2014 (%)... 107 FIGURE 19 GLOBAL MARKET FOR SLEEP AIDS: TECHNOLOGIES AND MARKETS BY REGION, 2008-2014 (%)... 107 TOTAL COMPETITIVE ANALYSIS OF THE SLEEP AIDS MARKET... 108 TABLE 29 TOP COMPETITORS IN SLEEP AIDS: TECHNOLOGIES AND GLOBAL MARKETS, 2009 ($ MILLIONS/%)... 108 FIGURE 20 TOP COMPETITORS IN SLEEP AIDS: TECHNOLOGIES AND GLOBAL MARKETS, 2009 (%)... 108 INDUSTRY PARTICIPANTS BY PRODUCT TYPE... 109 TABLE 30 SELECTED SLEEP AID DISORDERS TREATMENT MANUFACTURERS BY TYPE, 2009... 109 TABLE 30 (CONTINUED)... 110 CHAPTER SIX: COMPANY PROFILES... 111 CADWELL LABORATORIES, INC.... 111 BRIEF HISTORY... 111 PRODUCTS... 111 COMPANY REVENUE HISTORY... 112 CAREFUSION CORP.... 112 BRIEF HISTORY... 112 PRODUCTS... 112 COMPANY REVENUE HISTORY... 112 TABLE 31 COMPANY REVENUES, 2008 AND 2009... 112 CEPHALON, INC.... 113 BRIEF HISTORY... 113 PRODUCTS... 113 COMPANY REVENUE HISTORY... 114

TABLE 32 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 114 COMPUMEDICS, LTD. AUSTRALIA... 114 BRIEF HISTORY... 115 PRODUCTS... 115 COMPANY REVENUE HISTORY... 115 TABLE 33 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 116 DEVILBISS HEALTHCARE... 116 BRIEF HISTORY... 116 PRODUCTS... 116 COMPANY REVENUE HISTORY... 116 EMBLA SYSTEMS... 117 BRIEF HISTORY... 117 PRODUCTS... 117 COMPANY REVENUE HISTORY... 118 FISHER & PAYKEL... 118 BRIEF HISTORY... 118 PRODUCTS... 118 COMPANY REVENUE HISTORY... 118 TABLE 34 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 119 GLAXOSMITHKLINE... 119 BRIEF HISTORY... 119 PRODUCTS... 119 COMPANY REVENUE HISTORY... 120 TABLE 35 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 120 JOHNSON & JOHNSON... 120 BRIEF HISTORY... 120 PRODUCTS... 121 COMPANY REVENUE HISTORY... 121 TABLE 36 COMPANY REVENUES, 2008 AND 2009 ($ BILLIONS)... 121 KING PHARMACEUTICALS, INC.... 121 BRIEF HISTORY... 121 PRODUCTS... 122 COMPANY REVENUE HISTORY... 122 TABLE 37 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 122 MERCK & CO., INC.... 123 BRIEF HISTORY... 123 PRODUCTS... 123 COMPANY REVENUE HISTORY... 123 TABLE 38 COMPANY REVENUES 2007 AND 2008 ($ MILLIONS)... 123 NATUS MEDICAL, INC.... 124 BRIEF HISTORY... 124 PRODUCTS... 124 COMPANY REVENUE HISTORY... 124 TABLE 39 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 124

NEUROCRINE BIOSCIENCES, INC.... 125 BRIEF HISTORY... 125 PRODUCTS... 125 COMPANY REVENUE HISTORY... 125 TABLE 40 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 125 NOVADEL PHARMA, INC.... 126 BRIEF HISTORY... 126 PRODUCTS... 126 COMPANY REVENUE HISTORY... 126 TABLE 41 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 126 PFIZER, INC.... 127 BRIEF HISTORY... 127 PRODUCTS... 127 COMPANY REVENUE HISTORY... 127 TABLE 42 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 128 PHILIPS RESPIRONICS, INC.... 128 BRIEF HISTORY... 128 PRODUCTS... 129 COMPANY REVENUE HISTORY... 130 TABLE 43 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 130 RESMED, INC.... 130 BRIEF HISTORY... 130 PRODUCTS... 131 COMPANY REVENUE HISTORY... 131 TABLE 44 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 131 SANOFI-AVENTIS... 132 BRIEF HISTORY... 132 PRODUCTS... 132 COMPANY REVENUE HISTORY... 133 TABLE 45 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 133 SEALY CORP.... 134 BRIEF HISTORY... 134 PRODUCTS... 134 COMPANY REVENUE HISTORY... 135 TABLE 46 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 135 SELECT COMFORT CORP.... 135 BRIEF HISTORY... 135 PRODUCTS... 135 COMPANY REVENUE HISTORY... 136 TABLE 47 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 136 SEPRACOR, INC.... 136 BRIEF HISTORY... 136 PRODUCTS... 137 COMPANY REVENUE HISTORY... 137

TABLE 48 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 137 SLEEPMED, INC.... 138 BRIEF HISTORY... 138 PRODUCTS... 138 COMPANY REVENUE HISTORY... 138 SOMAXON PHARMACEUTICALS, INC.... 138 BRIEF HISTORY... 139 PRODUCTS... 139 COMPANY REVENUE HISTORY... 140 TABLE 49 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 140 TEMPUR-PEDIC INTERNATIONAL, INC.... 140 BRIEF HISTORY... 140 PRODUCTS... 141 COMPANY REVENUE HISTORY... 141 TABLE 50 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 142 UCB, INC.... 142 BRIEF HISTORY... 142 PRODUCTS... 143 COMPANY REVENUE HISTORY... 144 TABLE 51 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 144 VANDA PHARMACEUTICALS, INC.... 144 BRIEF HISTORY... 144 PRODUCTS... 144 COMPANY REVENUE HISTORY... 145 TABLE 52 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 145 XENOPORT, INC.... 145 BRIEF HISTORY... 145 PRODUCTS... 146 COMPANY REVENUE HISTORY... 146 TABLE 53 COMPANY REVENUES, 2008 AND 2009 ($ MILLIONS)... 146 APPENDIX A... 147 SLEEP ASSOCIATIONS... 147 AMERICAN ACADEMY OF SLEEP MEDICINE... 147 AMERICAN SLEEP APNEA ASSOC.... 147 AMERICAN SLEEP DISORDERS ASSOCIATIONS (ASDA)... 148 INTERNATIONAL SLEEP PRODUCTS ASSOC. (ISPA)... 148 NARCOLEPSY NETWORK, INC.... 148 NATIONAL CENTER ON SLEEP DISORDERS RESEARCH (NCSDR)... 148 NATIONAL FOUNDATION FOR SLEEP AND RELATED DISORDERS IN CHILDEN (NFSRDC)... 149 NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI)... 149 NATIONAL SLEEP FOUNDATION... 149

SLEEP MEDICINE RESEARCH FOUNDATION, INC.... 149 APPENDIX B... 150 TABLE 54 LIST OF PARTICIPATING COMPANIES... 150 TABLE 54 (CONTINUED)... 151 TABLE 54 (CONTINUED)... 152 TABLE 54 (CONTINUED)... 153 TABLE 54 (CONTINUED)... 154 TABLE 54 (CONTINUED)... 155 TABLE 54 (CONTINUED)... 156 TABLE 54 (CONTINUED)... 157 TABLE 54 (CONTINUED)... 158 TABLE 54 (CONTINUED)... 159 TABLE 54 (CONTINUED)... 160 TABLE 54 (CONTINUED)... 161 TABLE 54 (CONTINUED)... 162 TABLE 54 (CONTINUED)... 163 TABLE 54 (CONTINUED)... 164 TABLE 54 (CONTINUED)... 165 TABLE 54 (CONTINUED)... 166